Tegaserod-associated ischemic colitis.
Tegaserod, a potent partial agonist of the serotonin 5-HT4 receptor, is used to treat women with constipation-predominant irritable bowel syndrome. Since the drug's approval, the manufacturer has received infrequent although serious reports of diarrhea and ischemic colitis in patients taking the drug. These instances have led to a recent warning letter to physicians and a change in the prescription labeling of tegaserod. We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome. Potential mechanisms involved in the occurrence of ischemic colitis in patients receiving tegaserod are also discussed.
Mayo Clinic Scottsdale, Scottsdale, Arizonia, USA. Dibaise.john@mayo.edu
John K
JK
DiBaise
D000328:Adult; D017091:Colitis, Ischemic / Q000139:chemically induced* / Q000175:diagnosis / Q000209:etiology; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D043183:Irritable Bowel Syndrome / Q000150:complications / Q000188:drug therapy; D058828:Serotonin 5-HT4 Receptor Agonists; D017366:Serotonin Receptor Agonists / Q000009:adverse effects*
D007211:Indoles; D058828:Serotonin 5-HT4 Receptor Agonists; D017366:Serotonin Receptor Agonists; C105050:tegaserod